Krishna Institute of Medical Sciences (KIMS) Q4 23/24 earnings summary

Executive summary

• Consolidated revenue for FY24 reached ₹25,112 million, up 12.9% year-over-year, driven by expansion and higher patient volumes.

• EBITDA grew 3.7% to ₹6,535 million, while PAT declined 8.15% to ₹3,360 million due to higher depreciation and finance costs.

• IP and OP volumes increased by 7.9% and 9.9% respectively, with ARPOB rising 6.6% to ₹31,916.

• Major expansion included new hospitals in Nagpur, Nashik, and upcoming projects in Thane and Bengaluru.

Financial highlights

• Standalone revenue grew 7.1% to ₹12,376 million; standalone PAT fell 6.8% to ₹2,353 million.

• Consolidated EBITDA margin maintained at 26%, with a focus on cost optimization and phased recruitment.

• Net debt to equity ratio at 16.4% (consolidated), reflecting prudent capital management.

• Cash flow from operations remained strong at ₹5,211 million (consolidated).

Outlook and guidance

• Targeting addition of 2,000–2,500 beds over the next two years through new hospitals and expansions.

• Continued focus on expanding into Maharashtra and Karnataka, with new facilities in Thane and Bengaluru.

• Emphasis on specialty growth in oncology and mother & child care, leveraging the 'Cuddles' brand.

• Maintaining EBITDA margin above 25% by balancing new hospital ramp-up with mature facility profitability.